XCancer

Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) Alone and in Combination with Pembrolizumab in Subjects with Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates And/or Chemotherapy (TRACY-1)

Description:

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and with pembrolizumab in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

Sponsor:

RαyzeBio

Phase:

Phase 1/2

Contacts:

RayzeBio Clinical Trials

clinicaltrials@rayzebio.com

(619) 657-0302

Government Study Link:

NCT06590857 - Click here to see study on

ClinicalTrials.gov

RYZ101

Isotope(s):
Target(s):
  • SSTR+
Chelator: DOTA